163 related articles for article (PubMed ID: 26068177)
1. Cancer Stem Cell Markers Are Associated With Distant Hematogenous Liver Metastases But Not With Peritoneal Carcinomatosis in Colorectal Cancer.
Neumann J; Löhrs L; Albertsmeier M; Reu S; Guba M; Werner J; Kirchner T; Angele M
Cancer Invest; 2015; 33(8):354-60. PubMed ID: 26068177
[TBL] [Abstract][Full Text] [Related]
2. Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system.
Michl M; Heinemann V; Jung A; Engel J; Kirchner T; Neumann J
Pathol Res Pract; 2015 Aug; 211(8):601-9. PubMed ID: 26092596
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic biomarkers for metastatic colorectal cancer].
Neumann JH
Pathologe; 2016 Nov; 37(Suppl 2):180-185. PubMed ID: 27638531
[TBL] [Abstract][Full Text] [Related]
4. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
5. CD44 is of functional importance for colorectal cancer stem cells.
Du L; Wang H; He L; Zhang J; Ni B; Wang X; Jin H; Cahuzac N; Mehrpour M; Lu Y; Chen Q
Clin Cancer Res; 2008 Nov; 14(21):6751-60. PubMed ID: 18980968
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.
Huang X; Sheng Y; Guan M
Surg Oncol; 2012 Jun; 21(2):103-7. PubMed ID: 21764578
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis.
Bellizzi A; Sebastian S; Ceglia P; Centonze M; Divella R; Manzillo EF; Azzariti A; Silvestris N; Montemurro S; Caliandro C; De Luca R; Cicero G; Rizzo S; Russo A; Quaranta M; Simone G; Paradiso A
J Cell Physiol; 2013 Feb; 228(2):408-15. PubMed ID: 22740326
[TBL] [Abstract][Full Text] [Related]
8. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
[TBL] [Abstract][Full Text] [Related]
11. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma--their prognostic significance.
Okudela K; Woo T; Mitsui H; Tajiri M; Masuda M; Ohashi K
Pathol Int; 2012 Dec; 62(12):792-801. PubMed ID: 23252868
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer.
Horst D; Kriegl L; Engel J; Kirchner T; Jung A
Cancer Invest; 2009 Oct; 27(8):844-50. PubMed ID: 19626493
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic marker profiles for risk of distant metastases in colorectal cancer].
Neumann J; Reu S; Kirchner T
Pathologe; 2012 Feb; 33(1):39-44. PubMed ID: 22293788
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery.
Nakamura K; Iinuma H; Aoyagi Y; Shibuya H; Watanabe T
Oncology; 2010; 78(5-6):309-15. PubMed ID: 20616575
[TBL] [Abstract][Full Text] [Related]
17. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
18. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
19. CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.
Horst D; Kriegl L; Engel J; Jung A; Kirchner T
Eur J Cancer; 2009 Jul; 45(11):2034-40. PubMed ID: 19403300
[TBL] [Abstract][Full Text] [Related]
20. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer.
Galizia G; Gemei M; Del Vecchio L; Zamboli A; Di Noto R; Mirabelli P; Salvatore F; Castellano P; Orditura M; De Vita F; Pinto M; Pignatelli C; Lieto E
Arch Surg; 2012 Jan; 147(1):18-24. PubMed ID: 22250106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
